cancer is the most frequently encountered malignancy and the second leading cause of cancer-related death [3] . The prognosis of unresectable or recurrent tumors is very poor: the median survival time is about 4 months with best supportive care [4] [5] [6] . Although several randomized trials of treatments for advanced gastric cancer were conducted during the 1990s, with anthracyclines, mitomycin C, 5-fl uorouracil (5-FU), methotrexate, and cisplatin [7] [8] [9] [10] [11] [12] [13] [14] [15] , no standard treatment for advanced gastric cancer was established.
Introduction
Gastric cancer is the second leading cause of death from malignant disease in the world [1, 2] . In Japan, gastric Japanese. Considering this social background, chemotherapy for elderly cancer patients is an important issue that must be addressed. However, because gastric cancer patients who were more than 75 years old were not included in the three aforementioned Japanese phase III trials, elderly patients are generally administered monotherapy with S-1, which is not as intensive as S-1 plus cisplatin. However, the effi cacy and toxicity of S-1 monotherapy in elderly patients has not yet been clarifi ed.
In this study, we assessed the safety and effi cacy of S-1 monotherapy as a function of the age of patients with advanced gastric cancer.
Subjects, materials, and methods

Patients
The subjects were patients with unresectable or recurrent gastric cancer who received S-1 monotherapy at our hospital. The patient selection criteria were as follows: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2; histologically proven adenocarcinoma; no previous history of chemotherapy; adequate oral intake; adequate bone marrow, renal, and hepatic functions (defi ned as an absolute neutrophil count of ≥1500/μl, hemoglobin of ≥8.0 g/dl, serum creatinine of ≤1.5 mg/dl, serum transaminase levels less than threefold the upper limit of normal); and no concomitant malignancy. The presence of measurable lesions was not mandatory.
We categorized the patients into three groups, as follows; the young group (less than 66 years old), the middle-aged group (66 years or older, but not older than 75 years), and the elderly (more than 75 years old).
Treatment dose and schedule
S-1 was administered orally twice daily at the dose of 40 mg/m 2 from day 1 to day 28, followed by 14 days' rest, and this regimen was repeated every 42 days until disease progression, the appearance of unacceptable toxicities, or the patient's refusal to continue treatment. The dosage of S-1 was determined according to the body surface area (BSA), as follows: BSA less than 1.25 m , 60 mg bid. We suspended treatment during the cycle or delayed the treatment cycle until nonhematological toxicities recovered to grade 1 or lower, the neutrophil count was 1500/μl, and the platelet count was 7.5 × 10 4 /μl. The dose of S-1 was reduced by 20% (level 1) in the event of any of the following occurrences during the previous cycle: grade 4 decrease in the leukocyte count, hemoglobin, or platelet count; and/or grade 3 or higher nonhematological toxicities. If these toxicities appeared again at the reduced dose, an additional reduction of the dose of S-1 by 20% (level 2) was made. The treatment schedule of 2 weeks' administration every 3 weeks was permitted if severe adverse events were seen after the second week in each course. A dose reduction of S-1 by one level at the initiation of the therapy was also permitted considering the patient's age, PS, and organ functions.
Response and toxicity evaluation
We obtained all the clinical data from the medical records retrospectively. We repeated physical examinations and laboratory tests at least once every 2 weeks. Objective response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0, and toxicity was evaluated based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
Statistical analysis
Overall survival (OS) was defi ned as the period from the date of the fi rst administration of S-1 to the date of death from any cause or the last date on which the patient was confi rmed to be alive. Progression-free survival (PFS) was defi ned as the period from the date of the fi rst administration of S-1 to the date of confi rmation of tumor progression by imaging, or the date of symptomatic deterioration by clinical judgment, or the last date on which the patient was confi rmed to be alive without disease progression. Patients who had only the one noncurative factor of positive peritoneal washing cytology were excluded from the PFS and OS analyses, because it was suggested that these patients would survive longer than patients with other noncurative factors; however these patients' toxicities were assessed. Patients who did not have target lesions were also excluded from the response rate (RR) analysis. The survival curves were calculated by the Kaplan-Meier method, using StatView, version 5.0 (Abacus Concepts, Berkeley, CA, USA). Written informed consent was obtained from each of the patients prior to their starting the chemotherapy.
Results
Patient characteristics
A total of 165 patients received S-1 monotherapy between September 2002 and October 2007. Of these, 12 patients were excluded, for the following reasons: hepatic function disorder (5 patients), concomitant malignancy (3 patients), severe anemia (2 patients), renal failure (1 patient), and massive pleural effusion and/or ascites (1 patient).
The baseline characteristics of the patients in the three groups are shown in Table 1 . The median age was 59.5 years (range, 34 to 65 years) in the young group, 70 years (range, 66 to 75 years) in the middle-aged group, and 77 years (range, 76 to 80 years) in the elderly group. The percentage of patients with PS 2 was higher (20%) in the elderly group than in the other two groups. The median creatinine clearance (calculated by the Cockcroft-Gault equation) was 88.3 ml/min in the young group, 65.4 ml/min in the middle-aged group, and 59.9 ml/min in the elderly group. There were 32 (42%), 35 (56%), and 12 (80%) patients with target lesions, and 20 (26%), 12 (19%), and 1 (6%) patients with positive peritoneal washing cytology as the only noncurative factor in the young, middle-aged, and elderly groups, respectively.
Exposure to treatment
The median number of treatment cycles was 5.5 (range, 1 to 28) in the young group, 5 (range, 1 to 18) in the middle-aged group, and 3 (range, 1 to 13) in the elderly group. Dose reduction of S-1 was required in some patients in all three groups: in 12 patients (16%) in the young group, 14 patients (23%) in the middle-aged group, and 8 patients (53%) in the elderly group. Delay of the subsequent treatment cycle was also necessitated in some patients in all three groups: in 23 patients (30%) in the young group, 26 patients (42%) in the middleaged group, and 5 patients (33%) in the elderly group.
The median relative dose intensity (RDI) per patient in the elderly group was only 75.8%, whereas the corresponding values in the young and middle-aged groups were 99.5% and 96.3%. In 7 (47%) of the 15 patients in the elderly group, S-1 was administered at a reduced dose from the start, and in 8 patients in the elderly group (53%), the dose of S-1 was reduced due to the appearance of toxicity during the treatment courses, and 3 of these 8 patients needed additional dose reduction because of the development of severe adverse events.
The reasons for treatment discontinuation are shown in Table 2 . The most frequent reason in all three groups was disease progression. While two patients in the young group required treatment discontinuation because of the development of adverse events (grade 3 pneumonitis in one, and grade 2 skin rash in the other), none of the patients in the elderly group required treatment The P values were determined using the Kruskal-Wallis test PS, performance status; CCr, creatinine clearance; CY1, positive peritoneal washing cytology a Cockcroft-Gault equation discontinuation because of adverse events or the patient's refusal. Table 3 shows the adverse events until 30 days from the last administration of S-1 or the day of initiation of second-line treatment, whichever was earlier. The incidences of grade 3/4 decreases in the leukocyte count and serum hemoglobin were 7% and 9% in the young group, 5% and 18% in the middle-aged group, and 13% and 27% in the elderly group, respectively. One patient in the middle-aged group showed a grade 4 decrease in serum hemoglobin, and one patient in the young group showed grade 4 neutropenia. In regard to the nonhematological toxicities, the incidences of grade 3/4 nausea, anorexia, and fatigue seemed to be higher in the elderly group than in the other two groups. Thus, it would appear that patients in the elderly group experienced more severe hematological and nonhematological toxicities than those in the young and middle-aged groups, while the incidences of toxicities were similar in the young and middle-aged groups. One patient in the elderly group died within 30 days from the last administration of S-1. He was 80 years old, with PS 2, and the estimated creatinine clearance was 56 ml/min at the baseline. He received S-1 administration at a reduced dose even from the fi rst cycle because of his advanced age and anorexia caused by primary cancer. When he visited our hospital on day 17, he was found to have grade 2 mucositis. On day 23, he was admitted to another hospital because of severe anorexia and fatigue, and received some infusion therapy. However, he died on day 30 after the last administration of S-1. The attending physician judged that the cause of death was disease progression.
Adverse events
Response and survival
Among the patients with target lesions, the RR was 53% (17/32) in the young group, 46% (16/35) in the middle-aged group, and 33% (4/12) in the elderly group. Two patients (6%) in the middle-aged group showed a complete response (CR). The data of 56 patients in the young group, 50 in the middle-aged group, and 14 in the elderly group were analyzed in the calculations of the PFS and OS. The median PFS values in the young group, middle-aged group, and elderly group were 7.8 months, 5.6 months, and 3.9 months (Fig. 1) , and the median overall survivals Middle-aged (n = 62) The P values were determined using the Kruskal-Wallis test in the three groups were 16.9 months, 17.1 months, and 7.7 months, respectively (Fig. 2) . It would seem that the treatment effi cacy in the elderly group was inferior to that in the other two groups, while the young and middle-aged groups showed similar treatment effi cacy.
Discussion
It still remains under debate whether standard chemotherapies established by pivotal phase III trials might also be applicable to elderly patients with advanced gastric cancer [20] [21] [22] [23] . Lee et al. [24] conducted a randomized phase II study comparing capecitabine and S-1 in patients older than 65 years, and showed satisfactory effi cacy of S-1 (RR, 29%; median time to progression, 4.2 months; median OS, 8.1 months). In Japan, Koizumi et al. [25] conducted a phase II study of S-1 in patients older than 75 years and demonstrated a RR of 21%, median PFS of 3.9 months, and median OS of 15.7 months. Similar results were obtained in the elderly group in the present study. Because these results are consistent with those of the previous phase III studies in Japan [17] [18] [19] (RR of about 30% and PFS of about 4 months), it is considered that S-1 monotherapy may be effective in elderly patients with gastric cancer. However, elderly cancer patients often have comorbidities and age-related physiological problems, such as organ dysfunction. The kidney is a very common route for the excretion of drugs; however, it is reported that the glomerular fi ltration rate generally decreases by approximately 0.75 ml/min per year after the age of 40, on average [26] . In several pharmacokinetic studies of chemotherapeutic drugs, such as paclitaxel, vinorelbine, etoposide, cisplatin, and doxorubicin, an age-related decrease in creatinine clearance has been reported [23] .
Lee et al. [24] and Koizumi et al. [25] reported the following incidences of grade 3/4 toxicities: decrease in serum hemoglobin, 9%-14.3%; anorexia, 9.5%-12%; and nausea, 4.8%-6%. These data are similar to those in the middle-aged group in the present study (decrease in serum hemoglobin, 18%; anorexia, 6%; nausea, 5%). In the elderly group in the present study, the incidences of severe toxicities (decrease in serum hemoglobin, 27%; anorexia, 27%; nausea, 13%) were higher than those reported from the previous trials, despite about half of our elderly patients having received S-1 at a reduced dose from the fi rst administration. The conditions of patients in daily clinical practice are generally worse than those in patients participating in clinical trials. Actually, in the present study, the median creatinine clearance, estimated by the Cockcroft-Gault equation, was lower in the elderly group (59.9 ml/min) than the values in the middle-aged (65.4 ml/min) and younger (88.3 ml/min) groups. It is known that the clearance of CDHP is reduced by renal dysfunction, resulting in a high blood concentration of 5-FU due to decreased DPD activity [27, 28] . In a post-marketing survey of S-1, it was reported that the incidence of toxicities was greater in patients with renal dysfunction than in those with normal renal function [29] . Thus, it is considered that renal dysfunction is the main reason for the high incidence of severe S-1 toxicities in elderly patients. Therefore, careful evaluation of the renal function prior to the initiation of S-1 monotherapy is strongly recommended.
In conclusion, in the present study, although S-1 monotherapy exhibited moderate effi cacy in elderly patients (≥76 years of age) with advanced gastric cancer, this subject population is at a higher risk of severe toxicities than the other two age groups (66-75 years old and younger) examined in this study. Careful monitoring of renal function and toxicities during treatment is recommended, especially in elderly patients.
